Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 19/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 19/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 19/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 19/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 19/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 0.50 |
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013785 | 1.00 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4002917 | 0.92 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4002913 | 0.92 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1876361 | 0.76 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1872719 | 0.76 | PSEN1 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1875188 | 0.75 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5568532 | 0.75 | PSEN1 (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5568536 | 0.75 | PSEN1 (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1874419 | 0.74 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1875505 | 0.74 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569562-B2 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | claimed |
| EP-1838701-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2007-10-03 | — | — | EP | claimed |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | claimed |
| WO-2006078753-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| US-7569562-B2 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1838701-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006078753-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | SULT2A1, PSEN1, PSEN2 | PSEN1 2/4885PSEN2 3/4885APH1B 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.